Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.53 |
| ▸ | PDE4B known ✓ | Q07343 | 1/20 | 0.53 |
| ▸ | PDE4C known ✓ | Q08493 | 1/20 | 0.53 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.53 |
| ▸ | PTGS2 known ✓ | P35354 | 10/20 | 0.45 |
| ▸ | PTGS1 known ✓ | P23219 | 7/20 | 0.45 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.39 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084789 | 0.99 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DPTGS2 | |
| SCHEMBL2085162 | 0.99 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DPTGS2 | |
| SCHEMBL12936302 | 0.90 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DPTGS2 | |
| Hydrochloric Acid SCHEMBL2084966 | 0.90 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4DHRH4 | |
| SCHEMBL12936298 | 0.89 | PTGS2 (0.47) | PDE4APDE4BPDE4CPDE4DPTGS2 | |
| SCHEMBL2084625 | 0.89 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DHRH4 | |
| SCHEMBL2080997 | 0.87 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DPTGS2 | |
| SCHEMBL2085527 | 0.87 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DPTGS2 | |
| SCHEMBL13745003 | 0.83 | KDM4E (0.43) | PTGS2PTGS1KDM4EALDH1A1LMNA | |
| SCHEMBL2084572 | 0.81 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973884-B1 | NOVEL HETEROCYCLES | ORCHID PHARMA LTD (IN) | 2016-08-03 | — | — | EP | disclosed |
| US-8828999-B2 | Pyrimidine compounds and their uses | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2014-09-09 | — | — | US | disclosed |
| US-20130172350-A1 | PYRIMIDINE COMPOUNDS AND THEIR USES | ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2013-07-04 | — | — | US | disclosed |
| US-8420653-B2 | Pyrimidine compounds and their uses | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-04-16 | — | — | US | disclosed |
| US-7863446-B2 | Heterocycles | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2011-01-04 | — | — | US | disclosed |
| US-20100329998-A1 | NOVEL HETEROCYCLES | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2010-12-30 | — | — | US | disclosed |
| EP-2245017-A2 | NOVEL HETEROCYCLES | Orchid Research Laboratories Limited (IN) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009095773-A2 | NOVEL HETEROCYCLES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-08-06 | — | — | WO | disclosed |
| EP-1973884-A2 | NOVEL HETEROCYCLES | Orchid Research Laboratories Limited (IN) | 2008-10-01 | — | — | EP | disclosed |
| US-20080207606-A1 | Novel heterocycles | ORCHID RESEARCH LABORATORIES LIMITED. (IN) | 2008-08-28 | — | — | US | disclosed |
| WO-2007083182-A2 | NOVEL HETEROCYCLES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-07-26 | — | — | WO | disclosed |
| US-20070167413-A1 | Novel heterocycles | ORCHID RESEARCH LABORATORIES LIMITED. (IN) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207606-A1 | Novel heterocycles | GPR4, UACA, PDE4A | PDE4A 3/4885PDE4B 8/4885PDE4C 29/4885 |
| US-20100329998-A1 | NOVEL HETEROCYCLES | UACA, GPR4, CASP4 | PDE4A 4/4885PDE4B 6/4885PDE4C 23/4885 |
| US-20070167413-A1 | Novel heterocycles | MCL1, UACA, MYLK2 | PDE4A 3070/4885PDE4B 3237/4885PDE4C 3411/4885 |
| US-20130172350-A1 | PYRIMIDINE COMPOUNDS AND THEIR USES | UMPS, PNP, PDE4A | PDE4A 3/4885PDE4B 6/4885PDE4C 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.